Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that the company recently received a Drug Clinical Trial Approval Notice (acceptance number: CXZL2600062; notice number: 2026LP03037) issued by the National Medical Products Administration. The company's clinical trial application to add a new function and indication for Jidesheng Snake Medicine Tablet for the treatment of herpes zoster (liver-gallbladder damp-heat syndrome) has been approved.

Jidesheng Snake Medicine Tablet is an existing marketed product of the company. This approval relates to a clinical trial application for adding a new function and indication to an already marketed traditional Chinese medicine product, and will not have a significant impact on the company's current operating performance.